Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bardella, C.
Right arrow Articles by Di Renzo, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bardella, C.
Right arrow Articles by Di Renzo, M. F.
[Cancer Research 64, 5154-5161, August 1, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression

Chiara Bardella1, Barbara Costa1, Piera Maggiora1, Salvatore Patane’1, Martina Olivero1, Guglielmina N. Ranzani4, Michele De Bortoli2, Paolo M. Comoglio3 and Maria Flavia Di Renzo1

1 Laboratory of Cancer Genetics, 2 Functional Onco-Genomics Center, and 3 Division of Molecular Oncology, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Turin, Italy, and 4 Department of Genetics and Microbiology, University of Pavia, Pavia, Italy


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
RON is a tyrosine kinase receptor that triggers scattering of normal cells and invasive growth of cancer cells on ligand binding. We identified a short RON mRNA, which is expressed in human lung, ovary, tissues of the gastrointestinal tract, and also in several human cancers, including ovarian carcinomas and cell lines from pancreatic carcinomas and leukemias. This transcript encodes a truncated protein (short-form RON; sf-RON), lacking most of the RON receptor extracellular domain but retaining the whole transmembrane and intracellular domains. Sf-RON shows strong intrinsic tyrosine kinase activity and is constitutively phosphorylated. Epithelial cells transduced with sf-RON display an aggressive phenotype; they shift to a nonepithelial morphology, are unable to form aggregates, grow faster in monolayer cultures, show anchorage-independent growth, and become motile. We show that in these cells, E-cadherin expression is lost through a dominant transcriptional repression pathway likely mediated by the transcriptional factor SLUG. Altogether, these data show that expression of a naturally occurring, constitutively active truncated RON kinase results in loss of epithelial phenotype and aggressive behavior and, thus, it might contribute to tumor progression.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The RON receptor belongs to the MET family of tyrosine kinase receptors (1) . This family includes the human and mouse MET and the human RON and its homologues in mouse (stk; Ref. 2 ), cat (f-stk; Ref. 3 ), and chicken (sea; Ref. 4 ). Members of the family share biochemical features and biological properties. MET and RON receptors both trigger complex morphogenetic programs of epithelial cells that lead to "invasive growth" (5) . In physiological conditions, cell invasive growth occurs during organ development and regeneration. In cancer cells, inappropriate activation of invasive growth might lead cells to invade and metastasize.

The RON receptor is expressed in epithelia and hematopoietic cells. First findings (6) indicated that RON receptor activation regulates tissue macrophage motility. Additional findings demonstrated that the RON receptor induces epithelial cell scattering, which involves not only cell motility but also dissociation and matrix invasion, suggesting that RON might be involved in the pathogenesis of certain epithelial cancers (7) .

Activation of oncogenes of the MET family occurs in cancer and follows rules that are common to all of the tyrosine kinase oncogenes. MET and RON are overexpressed and amplified in human cancers of specific histotypes (7, 8, 9, 10) . Both MET and RON receptors can be activated by missense mutations in the tyrosine kinase domain. MET mutations have been found in families suffering from hereditary papillary renal cell carcinoma (11 , 12) . When the same mutations were introduced in the RON cDNA, mutated receptors converted transfected cells into tumorigenic transformants (13) . Rearrangement of both MET and RON genes with the dimerizing TPR sequences led to kinase activation, cell transformation, and tumorigenesis (14 , 15) .

Both the human RON and the homologous mouse stk genes give rise to two transcripts: in humans a 5.0 kb and a 2.0 kb mRNAs (16) ; and in the mouse a 4.5 kb and a 1.9 kb mRNAs (2) . In both species, the longer transcript encodes for the full-size receptor. The shorter mouse transcript (sf-stk) was found to be expressed in animals susceptible to Friend leukemia virus-induced erythroleukemia and absent in resistant mice (17) . In the latter, sf-stk-enforced expression restored susceptibility. In Friend-infected erythroblasts, the sf-stk protein directly interacts with viral gp55 but not with the erythropoietin-R (18) and plays a key role in the signal transduction that regulates erythropoietin-independent erythroblast expansion. Conversely, the sf-stk role in cell physiology is still elusive, although the sf-stk transcript is highly expressed in mouse erythroleukemic cells (2) and is detectable in mouse stomach and intestine (19) .

The shorter (2.0 kb) human RON mRNA was detected, at a very low level, in colon, skin, and lung tissues but not in bone marrow, bone-marrow-derived cells, human muscle, nor in human brain (16 , 20) . It has been also found in some human tumor cells lines derived from gastric (16) and lung cancers (21) . Although it is known that the shorter transcript includes sequences encoding the RON kinase domain, its role in normal and cancer tissues is still unknown.

In this article, we show that a 5'-truncated RON mRNA, analogous to sf-stk transcript, is expressed in human normal and cancer cells including ovarian, pancreatic, gastrointestinal, and leukemia cells. In well-differentiated breast carcinoma cells, its enforced expression induced loss of epithelial features and progression toward a more aggressive phenotype.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines and Human Tissues.
The GTL16 cell line is a clonal cell line derived from a poorly differentiated gastric carcinoma line (22) . All of the other cell lines were purchased from American Type Culture Collection (Manassas, VA). Normal and cancer human tissue samples were obtained and processed as described previously (23) .

Antibodies.
The purified polyclonal antibodies C-20 and N-20, antihuman RON, anti-SLUG, and the monoclonal antibodies against N-cadherin were from Santa Cruz Biotechnology (Santa Cruz, CA); monoclonal antibodies anti-E-cadherin were from Transduction Laboratories (BD Biosciences, Canada); monoclonal pan anticadherins antibodies were from Sigma (Sigma-Aldrich, Germany); and monoclonal antiphosphotyrosine antibodies were from Upstate (Upstate, MA). Monoclonal anti-myc antibodies (clone 9E10) were obtained from Dr. Luca Tamagnone (I.R.C.C., Candiolo, Torino, Italy).

End-Point Reverse Transcription-PCR (RT-PCR).
Cytoplasmic mRNA was prepared using the Concert Reagent from Invitrogen (Life Technology, Carlsbad, CA). Total RNA from tissue samples was prepared and analyzed as described previously (22) . Retrotranscription was carried out with Moloney murine leukemia virus reverse-transcriptase RNase H minus (Promega, Madison, WI) and oligodeoxythymidine nucleotide. To examine RON transcript expression, PCR was performed with the following primers: sense, 5' TAT CCT GCA GGT GGA GCT G 3'; and antisense, 5' ATG AAA TGC CAT GCC CTT AG 3'. PCR conditions were 10 min at 95°C for 1 cycle; 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C for 30 cycles; and 7 min at 72°C for 1 cycle, with DNA polymerase TaqGold (Perkin-Elmer). To detect sf-RON expression, seminested PCR was performed as follows. In both rounds of amplification, the sense primer was (P1, that anneals on an intron 10 sequence) 5' CCT CAT GAC CCT CTC TGC AGT 3'. In the first PCR round, the antisense primer was either P2, that anneals on a exon 14 sequence: 5'CAG CAG TGG CAC ACA GGA T3'or P3, that anneals on an exon 16 sequence: 5' TAC CAA TGA GAG CCA GCA CA 3'; in the second amplification round, the antisense primer was either P4, that anneals on a exon 12 sequence: 5' GCC ACC AGT AGC TGA AGA CC 3' or P5, that anneals on a exon 14 sequence: 5' CAG CAG TGG CAC ACA GGA T 3'. Both PCR amplifications were performed with DyNAzyme DNA (Finnzymes) polymerase at 3 min at 95°C for 1 cycle, 1 min at 95°C, 1 min at 56°C, 1min at 72°C for 20 cycles, and 7 min at 72°C for 1 cycle. To rule out the possibility that the identified RT-PCR products could derive from unprocessed nuclear RNA, cytoplasmic RNA was purified; control amplifications were performed with antisense primers corresponding to other intron sequences (data not shown) and showed that unprocessed RNA was not present.

To detect E-cadherin gene expression, RT-PCR was carried out with the following primers: sense, 5' TGG GTT ATT CCT CCC ATC AG 3'; and antisense, 5' TTT GTC AGG GAG CTC AGG AT 3'. PCR conditions were 3 min at 95°C for 1 cycle, 1 min at 95°C, 1 min at 59°C, 1 min at 72°C for 30 cycles, and 7 min at 72°C for 1 cycle, with DyNAzime (Finnzymes). For N-cadherin expression, the following primers were used: sense, 5' CGG GTA ATC CTC CCA AAT CA 3'; and antisense, 5'CTT TAT CCC GGC GTT TCA TC 3'. PCR conditions were 3 min at 95°C for 1 cycle, 1 min at 95°C, 1 min at 57°C, 1 min at 72°C for 30 cycles, and 7 min at 72°C for 1 cycle, with DyNAzime (Finnzymes).

Immunoprecipitation, Western Blotting, and in Vitro Kinase Assay.
Immunoprecipitation and Western blotting were carried out as described previously (23) . To precipitate sf-RON protein, antibodies against RON COOH-terminus were cross-linked to Protein A-Sepharose with dimethylpimelimidate (Pierce) according to manufacturer’s instructions.

Immunocomplex kinase assay was performed on proteins immunoprecipitated with either myc or RON antibody in 25 mM HEPES (pH 7.4), 5 mM MnCl2, and 100 µM DTT supplemented with 20 µCi [{gamma}-33P]ATP (specific activity > 2500 Ci/mmol; Amersham, United Kingdom) for 10 min at 25°C. When reported, cells were pretreated with 0.1 mM sodium orthovanadate for 1 h at 37°C. Proteins were separated on SDS-PAGE. To evaluate phosphotyrosine, gels were alkali treated.

Cell Transduction with Lentiviral Vectors (LV).
Cells were transduced using third-generation LVs (24) . As transfer vector, we used the pRRL.sin.PPT.hCMV.GFP.pre, where enhanced green fluorescent protein cDNA (XbaI-SalI fragment of 754 bp) was substituted with the full-length RON cDNA (XbaI-SalI fragment 4590 bp). Sf-RON cDNA was obtained by PCR amplification with the following primers: sense, 5' GGT ATC AAC GTG ACC GGT GGT GGT 3'; and antisense, 5' AGC TAA GCA GGT CGA CCC CAA GAA CTA AG 3'. The obtained AgeI-SalI fragment of 1562 bp was subcloned in the transfer vector above. The pRRL.sin.PPT.hCMV.GFP.pre vector was used as a control. Sf-RON-myc-tagged cDNA sequence was obtained by PCR amplification with the following primers: sense, 5' GCT CTA GAA GAG CTG CCA GCA CGA GTT C 3'; and antisense, 5' CGC GGA TCC TCA ATT CAG ATC CTC TTC TGA GAT GAG TTT TTG TTC AGT GGG CCG AGG AGG CTC 3'. The PCR product was digested XbaI-BamHI and subcloned in the transfer-multicloning site vector pRRL.sin.PPT.hCMV.MCS.pre digested with the same restriction enzymes. The luciferase reporter gene constructs pRRL.sin.PPT.Ecadpr.Luciferase.pre containing wild-type E-cadherin promoter sequence was obtained by substituting in the transfer vector pRRLsin.PPT.TetOminMMTV. luciferase.pre the sequence TET07minMMTV (XhoI-SalI fragment of 511 bp) with the sequence of E-cadherin wild-type promoter from –176 to +93. The transfer vector pRRL.sin.PPT.Tet07.Luciferase (8306 bp) was used as a control in the luciferase assay. Vectors stocks were produced by transient transfection of 293T cells. Serial dilutions of freshly harvested media were used to infect 105 cells in a six-well plate in the presence of Polybrene (8 µg/ml). The viral p24 antigen concentration was determined by HIV-1 p24 core profile ELISA Innotest HIV antigen monoclonal antibody (Innogenetics N.V.).

Luciferase Assay.
To assay luciferase activity driven by E-cadherin or TET promoter, cells (0.15 x 106 in six-well plates) were transduced with LVs and, after 3 days, solubilized according to the Luciferase Assay System kit (Promega). Luciferase activity was measured with luminometer (Lumat LB 9507; EG&G Berthold). Three LV concentrations were assayed. Each concentration was assayed in two separate transduction experiments. Luciferase activity was expressed as relative light units normalized for total protein in each sample.

Quantitative Real-Time RT-PCR.
Expression of E-cadherin repressors was measured with quantitative real-time RT-PCR with TaqMan assay using SYBR green (Applied Biosystems, Foster City, CA) on cDNAs reverse transcribed from mRNA of sf-RON, over-RON, mock-transduced, and wild-type T47D cells. Forward and reverse primers for each gene were as follows: (a) to detect SLUG expression, forward primer 5' GTT TTC CAG ACC CTG GTT GCT 3' and reverse primer 5' TTC TCC CCC GTG TGA GTT CTA 3'; (b) to detect SNAIL expression, forward primer 5' CTC TGG TCT GAC CGA TGT GTC TC 3' and reverse primer 5' ACC TGT CGG GCC CCC 3'; (c) to detect E12/E47 expression, forward primer 5' TTT TGC CAT GAG GGT AAC CAG 3' and reverse primer 5' ACC CAA GAC AGT CCC AGC C 3'; and (d) to detect SIP1 expression, forward primer 5' GCT TGG TTA GCA GGT ATT TTG ACC 3' and reverse primer 5' CAA GAT GGC TCA TCA GCT AAA TCA 3'. Preliminary experiments were carried out to select primer pairs and concentrations. PCR reactions were carried out using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Oak Brook, IL). Glyceraldehyde-3-phosphate dehydrogenase expression was measured using the Perkin-Elmer glyceraldehyde-3-phosphate dehydrogenase kit.

Cell Growth Assays.
To measure proliferation rate, cells were plated (2 x 105 cells/well) in duplicate in six-well plates. Cell viability was evaluated by trypan blue exclusion assay. For soft agar growth assay, cells were suspended in 0.5% SeaPlaque agar (BMA, Rockland, ME) with complete RPMI 1640 and plated at the density of 250 or 750/ml. Colonies were stained with tetrazolium salt.

Cell Adhesion, Aggregation, and Motility Assays.
For cell adhesion assays, 96-well microtiter plates (Nunc, Naperville, IL) were coated with 0.1 µg/µl either laminin or fibronectin (Sigma) in Tris-buffered saline (pH 7.4) for 16 h at 4°C; wells were then rinsed and treated with 0.2% BSA in PBS (pH 7.4). Cells were harvested with 5 mM EDTA in PBS and seeded in serum-free medium (1.25–5 x 104 cells/well). After 15-, 30-, and 60-min incubation at 37°C, adherent cells were fixed in 11% glutaraldehyde, stained with 0.1% crystal violet, and counted. As control, cells were left to adhere to wells coated with BSA. For hanging drop assay, cells were harvested with 5 mM EDTA in PBS and resuspended in RPMI without serum and with or without 5 mM EGTA. Then, 50 µl of medium containing 10000 cells were seeded on the cover of a plastic culture plate and inverted; cell drops were incubated 5 h at 37°C and then photographed. Motility assay was carried out as described previously (23) .


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of the sf-RON in Human Cancers.
The homology between the sequence of human RON and mouse stk genes (Ref. 25 ; data not shown) suggested that the short RON transcript could be generated in the same way as the mouse sf-stk transcript, which starts in intron 10 and is translated from an ATG codon located in exon 11 (2 , 17) .

We first amplified human RON short transcript (sf-RON) sequences from normal human tissues (Fig. 1)Citation . As the RON/stk tyrosine kinase domain showed homologies with other kinase receptors (2 , 20) , we performed a seminested RT-PCR. We used intron 10 sequence as a sense primer in both rounds of amplification and two sequences as antisense primers selected to avoid amplification of the highly homologue human MET sequences. Two RT-PCR products were amplified consistently from tissues of the gastrointestinal tract, lung, and ovary but not from the liver nor both cardiac and skeletal muscle samples (Fig. 1)Citation . The two RT-PCR products were directly sequenced. One was found containing intron 10 and subsequent RON exons and was analogous to the sf-stk transcript. The second PCR product, more evident in lung tissues, contains also intron 11 and corresponded to an expressed sequence tag cloned previously from human lung tissues (PMO-ET0274-180301-001-c06). The two products are consistent with two spliced forms of the sf-RON transcript.



View larger version (57K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression of short-form RON transcript in human tissues and cancers. Reverse transcription-PCRs (RT-PCR) were carried out on cytoplasmic mRNA extracted from tissue samples and cell lines indicated above panels. Short-form-RONspecific product (top photographs) was amplified from normal human tissues (A), cancer samples (B), and cancer cells lines (C). The bottom photographs of each panel show control RT-PCRs with primers specific for glyceraldehyde-3-phosphate dehydrogenase cDNA. Two amplified products were obtained in seminested RT-PCR using a sense primer (P1; see "Materials and Methods") made of RON intron 10 sequence in both PCRs and as antisense primers exon 14 sequence (P2; see "Materials and Methods") in the first and exon 12 sequence (P4 primer; see "Materials and Methods") in the second PCR round. Direct sequencing of PCR product showed that the top band contained RON intron 10, exon 11, intron 11, and exon 12. The bottom band was made of intron 10 followed by exons 11–12.

 
Then, we evaluated sf-RON expression in 41 cell lines, representing different human tumor histotypes (Table 1)Citation . Approximately 50% of these cells showed expression of the sf-RON. These were mostly pancreatic carcinoma and hematopoietic cell lines (Table 1Citation ; Fig. 1Citation ). The transcript coding the full-size RON receptor was present in several cell lines, where the sf-RON transcript was not detectable (Table 1)Citation .


View this table:
[in this window]
[in a new window]

  		Table 1 Expression of the long and short RON transcripts in human cancers

 
We also examined breast and ovarian cancer samples and found sf-RON expression in 9 of 9 ovarian samples (9 serous carcinomas) examined and in ~30% of breast ductal carcinoma samples (Table 1)Citation .

We used immunohistochemistry to localize RON proteins in ovarian cancer samples and in the normal ovarian superficial epithelium, from which >95% of cancers derive. Antibodies were against the COOH-terminal tail of the RON kinase and, therefore, able to label both the full-size RON receptor and the sf-RON. The RON kinase domain was undetectable in the human ovarian superficial epithelium (Ref. 23 ; data not shown), demonstrating that neither the full-size nor the short-form RON protein is detectable in ovarian superficial epithelium. The nine ovarian carcinoma samples were all positive (data not shown).

Kinase Activity of the sf-RON Protein.
To study sf-RON biochemical and biological activities, expression in human cells was obtained using lentivirus-mediated gene transfer. The LVs allow efficient gene transfer (transduction) without cell selection, by driving the random integration of one or more copies of transgenes in each cell at different sites. As nondividing cells also are transduced, transgenes are integrated into the large majority of infected cells. Random integration ensures expression in almost all of the cells, because expression is not influenced by integration site. Because of a deletion in the long terminal repeat promoter region of LVs, integrated transgenes are transcribed only from the internal promoter that is present in the expression cassette.

Transduction of human cells with myc-tagged sf-RON showed that the identified transcript encodes a Mr 55,000 protein (Fig. 2A)Citation , which shows constitutive intrinsic tyrosine kinase activity (Fig. 2B)Citation .



View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Identification and kinase activity of the short-form RON (sf-RON) protein. Human 293T cells were transduced with lentiviral vectors carrying either myc-tagged sf-RON transgene (sf-RON) or the enhanced green fluorescent protein transgene (mock). A, the p55 sf-RON peptide is recognized in Western blot analysis (W.B.) by anti-myc and anti-RON antibodies, before and after immunoprecipitation (I.P.) with anti-myc antibodies. B, the intrinsic kinase activity of the sf-RON protein is assayed in an in vitro kinase assay; the addition of [{gamma}-33P]ATP resulted in tyrosine phosphorylation of the myc-tagged sf-RON protein (P-p55) immunoprecipitated with anti-myc antibodies. The sf-RON protein autophosphorylation is more evident in cells pretreated with sodium orthovanadate (NaVO3). Tyrosine phosphorylation was confirmed by alkali treatment of the PAGE gel (data not shown).

 
To evaluate the biological outcome of sf-RON protein expression, we transferred sf-RON cDNA into T47D breast carcinoma cell lines, again using LVs. We selected T47D cells as a model of well-differentiated transformed cells that maintain in vitro the ability to form cell cell-cell junctions (26) . In addition, in T47D cells, the RON receptor-encoding transcript is expressed highly, whereas RON short transcript is barely detectable (Fig. 3Citation ; Ref. 16 ). As controls, the same cells were transduced with the cDNA encoding the full-size RON receptor to obtain overexpression, and with a nonrelated transgene, encoding the enhanced green fluorescent protein, as a control. As the RON gene behaves as an oncogene, overexpression or expression of its possibly activated counterparts results in activation of cellular functions (27) .



View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Expression and activation of the short-form RON (sf-RON) protein in human breast cancer cells. Human T47D breast cancer cells were transduced with lentiviral vectors carrying the sf-RON transgene (sf-RON), the enhanced green fluorescent protein transgene (mock), or RON receptor-encoding transgene (over-RON). In A–C, the sf-RON protein (p55) and the full-size RON receptor (p150) were immunoprecipitated from lysates of T47D using an immunopurified anti-RON polyclonal antibody covalently conjugated to Protein A-Sepharose beads, to facilitate visualization of the Mr 55,000 sf-RON peptide. A, Western blot analysis of the precipitated protein with the same anti-RON antibody: (a) control refers to control precipitation with nonrelated antibody; and (b) the two sf-RON lanes show the results of separate T47D-transduction experiments with sf-RON cDNA-carrying lentiviral vectors. B, Western blot with antiphosphotyrosine antibodies; both the phosphorylated p150 RON receptor (P-p150) and the p55 sf-RON protein (P-p55) were more evident in cells pretreated with sodium orthovanadate (NaVO3). C, in vitro kinase assay: (a) the intrinsic kinase activity of both the p150 RON receptor and the p55 sf-RON protein is shown after the addition of [{gamma}-33P]ATP to the precipitated proteins; (b) in vitro phosphorylation was more evident in cells pretreated with sodium orthovanadate (NaVO3); and (c) the experiment confirms the strong intrinsic kinase activity of the p55 sf-RON and suggest that, when coimmunoprecipitated with the p150 RON receptor, p55 sf-RON contributes to its in vitro phosphorylation. Tyrosine phosphorylation was confirmed by alkali treatment of the PAGE gel (data not shown).

 
After transduction of T47D cells, we measured the number of integrated transgene copies and the corresponding mRNA by Southern blot analysis, PCR, and RT-PCR. As expected in both sf-RON-transduced T47D cells (sf-RON T47D) and in cells transduced with the full-size RON (over-RON T47D) transgenes, we found multiple and random transgene integration sites and the transgene mRNAs encoding the RON proteins (data not shown).

Fig. 3ACitation shows that in T47D cells transduced with the sf-RON transgene, a newly expressed protein with the Mr 55,000 is recognized by an anti-RON antibody raised against the COOH-terminal sequence of the full-length RON receptor. This sf-RON protein appeared phosphorylated on tyrosine in transduced cells (Fig. 3B)Citation . In the in vitro kinase assay (Fig. 3C)Citation , the p55 sf-RON protein showed intrinsic kinase activity (Fig. 3C)Citation , which was stronger than that of both the endogenous and the overexpressed RON full-size receptors. In fact, sf-RON phosphorylated to a higher intensity the coprecipitated full-size RON receptor.

Loss of Cell-Cell Adhesion of sf-RON Expressing Cells.
Both expression of either sf-RON or overexpression of the RON receptor caused morphological changes of T47D cells (Fig. 4A)Citation . Cells expressing the sf-RON appeared spherical, whereas those overexpressing the full-length RON receptor were more elongated than mock-transfected T47D. As these morphological changes can be attributed to adhesive molecule changes, we tested cell ability to adhere to extracellular matrix glycoproteins and to form cell aggregates independently from anchorage to substratum. Sf-RON T47D cells did not show any differential adhesion to laminin and to fibronectin (data not shown) but demonstrated a total inability to form cell aggregates in an in vitro assay (Fig. 4BCitation , top panels). To assess calcium-dependence of cell ability to form aggregates in this assay, we also performed the assay in the presence of the chelating agent EGTA. As shown in the bottom panel of Fig. 4BCitation , cell aggregation was completely inhibited by EGTA.



View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Loss of cell-cell adhesion of short-form RON (sf-RON) expressing cells. A, cultured T47D cells transduced with either sf-RON-encoding (sf-RON) or RON receptor-encoding (over-RON) transgenes changed morphology, whereas those expressing the enhanced green fluorescent protein transgene (mock) maintained the parental flat epithelial-like morphology. B, hanging drop assay of cell aggregation carried out in the absence (top panels) or presence (bottom panels) of the chelating agent EGTA. Mock-transduced T47D cells spontaneously formed aggregates in this assay. Cells transduced with the RON receptor-encoding transgene maintained this property, which was lost in cells transduced with the sf-RON-encoding transgene. The presence of the chelating agent abrogated cell ability to aggregate. C, cadherin expression evaluated by immunoprecipitation followed by Western blot analysis with the indicated antibody. D, E- and N-cadherin expression evaluated by RT-PCR.

 
Change of morphology and loss of calcium-dependent aggregation in sf-RON expressing cells suggested that cadherin function was impaired in these cells. Therefore, we tested whether nontransduced or transduced T47D cells expressed E-cadherin, other epithelial cadherins, or nonepithelial cadherins (Fig. 4C)Citation . Nontransduced T47D cells expressed E-cadherin and showed a modest reactivity with pan-specific antibodies that recognize a series of other cadherins (data not shown in Fig. 4CCitation ). Sf-RON T47D cells have lost E-cadherin and did not express detectable levels of the cadherins recognized by pan-specific antibodies (data not shown). Over-RON T47D cells have lost E-cadherin expression but showed neoexpression of other cadherins that might account for their ability to form aggregates. In particular, these cells showed neoexpression of the neuronal specific N-cadherin. This suggested that sf-RON activation directly affected cadherin(s) expression.

To assess whether E-cadherin loss was because of transcriptional or posttranscriptional regulation, mRNAs encoding either E- or Ncadherin were evaluated using end-point RT-PCR. As shown in Fig. 4DCitation , sf-RON T47D cells did not contain either E- or N-cadherin-specific transcript. On the contrary, E- but not N-cadherin transcript was detected in nontransduced T47D cells, whereas N-cadherin alone but not E-cadherin mRNA was found in over-RON T47D cells (Fig. 4D)Citation . This suggested that E-cadherin expression was turned off in both sf-RON and over-RON T47D cells at transcriptional level.

Sf-RON Expressing Cells Showed Faster Growth and Motility.
There are several truncated tyrosine kinases (28) that are able to confer a transformed phenotype to human cells. Furthermore, it is known that E-cadherin loss is directly associated to proliferation of transformed cells (29) .

Therefore, we measured proliferation of sf-RON expressing and RON overexpressing T47D cells in monolayer cultures and in soft agar. Sf-RON T47D cells grew faster than both the nontransduced ones, the mock-transduced, and over-RON T47D cells in monolayer culture (Fig. 5A)Citation . In addition, sf-RON expression conferred to T47D cells the ability of very fast growth in the absence of anchorage (Fig. 5B)Citation .



View larger version (36K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Growth and motility of short-form RON (sf-RON) expressing cells. A, cell growth in monolayer cultures; sf-RON expressing T47D cells (sf-RON) proliferated faster when grown in 60-mm diameter dishes in the presence of 10% FCS. At each time point, the indicated cell number is the median of three separate dishes; bars, ±SD. B, cell anchorage-independent growth in soft agar; sf-RON, seeded at the concentration of 750 cells/ml, formed colonies that became visible at the naked eye 7 days after plating, whereas mock-transduced and RON receptor-overexpressing cells (over-RON) formed a lower number of smaller colonies, visible after only after 21 days with magnification. C, cell motility assayed as ability to pass through the 8-µm diameter pores of a Transwell chamber filter. Nontransduced (wild-type) and sf-RON expressing T47D cells were seeded in the upper chamber of Transwell plates in the presence of the indicated concentration of FCS. Cells in the lower chamber were counted 48 h after plating. Numbers are from representative experiments; values represent the median cell number in 10 fields of two filters ±SD.

 
A role of E-cadherin in tumor progression is attributed to the acquisition of a motile and invasive phenotype by transformed cells. We measured cell motility in an in vitro assay and found that sf-RON expression increased significantly the ability of T47D cells to move through filter micropores (Fig. 5C)Citation .

Transcriptional Repression of E-Cadherin in sf-RON Expressing Cells.
E-cadherin gene expression in human cancers is silenced by a variety of mechanisms. Among them, in breast carcinoma cells, dominant transcriptional defects prevail because of a repression pathway mediated by molecules acting on E-cadherin proximal promoter (30) . To test this hypothesis in sf-RON and over-RON cells, we subcloned reporter gene construct made of luciferase gene in LVs under the control of the E-cadherin proximal promoter critical region extending from –176 to +93 of the E-cadherin gene sequence. The latter region has been identified as the minimal portion of E-cadherin promoter, demonstrating strong activity in breast cancer cell lines with intact E-cadherin transcription and greatly reduced activity in breast cancer cell lines defective for E-cadherin transcription (30 , 31) . Three days after transduction, on obtaining transgene integration, luciferase gene expression was evaluated. The reporter gene expression was repressed in both sf-RON and over-RON T47D cells, in the former to <0.1 and in the latter to <0.25 of the expression found in both nontransduced or mock-transduced cells (Fig. 6A)Citation .



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Transcriptional repression of E-cadherin in short-form RON (sf-RON) expressing cells. A, repression of E-cadherin promoter function. Sf-RON (sf-RON) or RON-receptor expressing (over-RON) T47D cells were compared with those expressing the enhanced green fluorescent protein. The E-cadherin promoter was subcloned in lentiviral vectors carrying luciferase gene as reporter. The indicated T47D cells were transduced with these vectors and assayed after 72 h. Luciferase activity was assayed in cell extracts. Luciferase expression driven by the E-cadherin promoter was compared with that powdered by the TET promoter in the absence of transactivator (basal activity). The activity of the E-cadherin promoter was reduced greatly in cells expressing sf-RON protein or overexpressing the RON receptor. B, expression of the E-cadherin repressor SLUG, SNAIL, E12/E47, and SIP1 messenger RNAs. The amount of each repressor was measured using quantitative reverse transcription-PCR with TaqMan assay. The level of each repressor mRNA was relative to that of glyceraldehyde-3-phosphate dehydrogenase mRNA and calculated by the equation 2–(CT,SLUG/SNAIL/E12/SIP1-CT,GAPDH). The amount is expressed as fold increase versus that measured in nontransduced T47D cells. C, Western blot analysis of SLUG protein expression. Either total proteins (right panel) or proteins immunoprecipitated by anti-SLUG antibodies (left panel) were labeled in Western blot analysis with the same anti-SLUG antibodies. In the immunoprecipitates, the antibodies labeled specifically a protein, which was increased in sf-RON expressing cells (left arrow). The same protein was precipitated from control breast carcinoma MDA-MB435 cells, which are known to express SLUG. In Western blot of total proteins, a comigrating protein was labeled specifically by anti-SLUG antibodies in sf-RON cell (right arrow) but not in mock-transduced cell extracts. Bars, ±SD. RLU, relative light unit; A.U., arbitrary unit.

 
Several repressors of the E-cadherin promoter activity have been identified. We measured the expression of SNAIL (32 , 33) , SLUG (31) , E12/E47 (34) , and SIP1 (35) . As shown in Fig. 6BCitation , the expression of SLUG was increased strongly in both sf-RON and over-RON T47D, although it was barely detectable in nontransduced cells, whereas the expression of the other repressors was very modestly affected. Altogether, these data show that the RON kinase activation induced E-cadherin transcription repression that could be because of increased expression of the SLUG repressor.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this article, we provide evidence that a truncated RON kinase is expressed in human cancers. The presence of a RON transcript, shorter than that encoding the full-size RON receptor, had been already demonstrated by Northern blot analysis in some normal tissues, cancer samples, and cell lines (16 , 20 , 21) . However, its role in physiology and pathology has never been explored. The murine homologue short-form stk is expressed highly in some mouse tissues, but its physiological role has not been established as yet, except in the Friend leukemia virus infection.

We found expression of sf-RON, detected as a transcript containing RON gene intron 10 sequences, homologous to the sf-stk transcript, in human tissues of the gastrointestinal tract, lung, and ovary. Expression in the gastrointestinal tract and lung was expected, because the shorter RON transcript has been detected already in the intestine (16) and was found to be the major one in the lung (20) . Sf-RON expression in the ovaries is a novel finding and is particularly intriguing. We found previously that the RON longer transcript was not expressed in a number of samples of human adult ovaries and in a percentage of ovarian carcinomas (23) . In mice, germ-line ablation of the RON TK domain leads to reduced ovarian size, due mainly to reduced number and density of corpora lutea and defects in ovulation (36) . The latter data imply that the RON kinase plays a role in the development of mouse ovary and, in particular, in follicles and their derivatives. The discovery of sf-RON expression in the human adult ovaries suggests that the RON kinase might be important in human ovaries, too.

Expression of sf-RON was found in ~50% of the tumor cell lines analyzed and in a number of cancer samples. All of the ovarian cancer samples and cell lines derived from gastrointestinal carcinomas, including all of the pancreatic carcinoma cell lines, expressed the short RON transcripts. It is worth noting that normal pancreas tissues did not show short RON transcript expression. In the normal ovary, using immunohistochemistry, we did not detect RON protein in the surface epithelium, from which >95% of human ovarian cancers derive (Ref. 23 ; data not shown), whereas we detected positive staining in ~50% of ovarian carcinomas examined (23) . This information suggests that sf-RON expression increase during ovarian cancer tumorigenesis. It is worth mentioning that we fully confirmed RON longer and shorter transcript expression in cell lines and tissues, where either transcript was identified previously with Northern blot analysis (16) .

Expression of the sf-RON transcript is low in most cancer cell lines (16 , 21) . However, we show that aberrant sf-RON expression provides striking biological outcomes, because it causes well-differentiated breast carcinoma cells to change morphology, move, and proliferate faster, even if in the absence of anchorage. Overexpression of the full-size RON receptor has milder biological outcomes. Difference is likely because of the higher and constitutive kinase activity of the sf-RON protein. Truncated forms of other tyrosine kinase receptors show ligand-independent activation leading to cell transformation (28) . For instance, the truncated epidermal growth factor receptor is expressed in a consistent percentage of human glioblastoma and transforms cells (37) .

Other naturally occurring RON variants show oncogenic potential (7) . All of these variants have in-frame deletions that lead to the RON kinase constitutive activation and cause activation of either cell growth in transformation assays or cell motility in invasion assays. These variants have been found only in a few cell lines and human tumor samples derived from gastrointestinal tract tissues. Before the discovery of these variants, the RON oncogene was converted into an oncogene by molecular approaches, including translocation with dimerizing sequences and experimental mutagenesis. Altogether, experimental approaches confirm that deregulation of RON kinase activity is essential to release RON oncogenic potential.

We report here that morphological changes and the transformed phenotype of sf-RON expressing cells are associated to loss of E-cadherin. Several observations led also to establish a direct correlation between E-cadherin loss and both cancerogenesis and tumor progression. We found that sf-RON expressing cells show not only a morphological change but also an increased proliferation rate. This reflects what occurs in cancer cells, where E-cadherin loss is associated to an increased proliferation rate, which, in some instances, directly depends on the protein loss, because it is counteracted by E-cadherin addition (29) .

E-cadherin is a tumor and invasion suppressor in human carcinomas. Its inactivation by mutations has been only occasionally found (38) . In fact, in most cases, E-cadherin down-modulation during tumor progression occurs by either promoter hypermethylation (39) or dominant transcriptional repression (40) . In particular, the identification of specific transcriptional repressors like SLUG, SNAIL, E12/E47, and SIP1 has greatly increased our understanding of E-cadherin regulation (31 , 33) . In addition, in most cancer cells where tyrosine kinases are activated, E-cadherin is lost as a consequence of its tyrosine phosphorylation leading to endocytosis and degradation or relocalization of the protein. For instance, MET tyrosine kinase activation results in E-cadherin loss by endocytosis because of E-cadherin ubiquitination (41) . We show that in sf-RON expressing cells, E-cadherin transcriptional repression is associated to increased SLUG expression, whereas expression of SNAIL, E12/E47, and SIP1 was substantially unaffected. We cannot rule out that other repressors might be involved, but SLUG was described already as E-cadherin-specific repressor in breast cancer cells (31) .

In conclusion, we show a novel mechanism by which an activated tyrosine kinase of the MET family leads to E-cadherin loss, which accompanies the acquisition of a more transformed phenotype by cancer cells. Receptors of the MET family have been already implicated in tumor progression toward an invasive and metastatic phenotype (5) . This phenotype acquisition has been shown to depend on qualitative and quantitative activation of specific signal transduction cascades but can be limited or rapidly reversed in many cases. Here, we report that a constitutively active kinase of the same family, which is expressed in human tumor cells, determines a morphological subversion and the acquisition of a more aggressive phenotype by suppressing E-cadherin expression at mRNA level. This suggests that besides transient and acute alteration of cell behavior, kinases of the MET family can orchestrate the transformed and aggressive phenotype of cancer cells by stably inducing transcriptional activation and repression.


   ACKNOWLEDGMENTS
 
We thank Enzo De Sio, Lucia Sergi Sergi, and Raffaella Albano for technical help, Elaine Wright for reading the English, and Prof. Luigi Naldini, Dr. Elisa Vigna, and Dr. Livio Trusolino for precious suggestions and helpful discussion.


   FOOTNOTES
 
Grant support: Italian Ministry of Research and Education (Ministero per l’Istruzione, l’Universita’ e la Ricerca Scientifica; M. Di Renzo, P. Comoglio, M. De Bortoli, and G. N. Ranzani), the Italian National Research Council (Consiglio Nazionale delle Ricerche-Ministero per l’Istruzione, l’Universita’ e la Ricerca Scientifica Progetto Oncologia), and the Italian Association for Cancer Research (Associazione Italiana Ricerca sul Cancro; M. Di Renzo and P. Comoglio).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Maria Flavia Di Renzo, Laboratory of Cancer Genetics, Istituto per la Ricerca e la Cura del Cancro, SP 142, Km 3.95, 10060 Candiolo (TO), Italy. Phone: 39-11-9933343; Fax: 39-11-9933524; E-mail: mariaflavia.direnzo{at}ircc.it

Received 2/19/04. Revised 4/29/04. Accepted 5/19/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature (Lond), 411: 355-65, 2001.[CrossRef][Medline]
  2. Iwama A, Okano K, Sudo T, Matsuda Y, Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood, 83: 3160-9, 1994.[Abstract/Free Full Text]
  3. De Maria R, Maggiora P, Biolatti B, et al Feline STK gene expression in mammary carcinomas. Oncogene, 21: 1785-90, 2002.[CrossRef][Medline]
  4. Huff JL, Jelinek MA, Borgman CA, Lansing TJ, Parsons JT. The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc Natl Acad Sci USA, 90: 6140-4, 1993.[Abstract/Free Full Text]
  5. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev Cancer, 2: 289-300, 2002.[CrossRef][Medline]
  6. Leonard EJ, Danilkovitch A. Macrophage stimulating protein. Adv Cancer Res, 77: 139-67, 2000.[Medline]
  7. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis (Lond), 24: 1291-300, 2003.[Abstract/Free Full Text]
  8. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res, 55: 1129-38, 1995.[Abstract/Free Full Text]
  9. Di Renzo MF, Olivero M, Giacomini A, et al Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res, 1: 147-54, 1995.[Abstract]
  10. Maggiora P, Marchio S, Stella MC, et al Overexpression of the RON gene in human breast carcinoma. Oncogene, 16: 2927-33, 1998.[CrossRef][Medline]
  11. Schmidt L, Duh FM, Chen F, et al Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet, 16: 68-73, 1997.[CrossRef][Medline]
  12. Olivero M, Valente G, Bardelli A, et al Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer, 82: 640-3, 1999.[CrossRef][Medline]
  13. Santoro MM, Penengo L, Minetto M, et al Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene, 17: 741-9, 1998.[CrossRef][Medline]
  14. Gonzatti-Haces M, Seth A, Park M, et al Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci USA, 85: 21-5, 1988.[Abstract/Free Full Text]
  15. Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol, 16: 7072-83, 1996.[Abstract]
  16. Gaudino G, Follenzi A, Naldini L, et al RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J, 13: 3524-32, 1994.[Medline]
  17. Persons DA, Paulson RF, Loyd MR, et al Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet, 23: 159-65, 1999.[CrossRef][Medline]
  18. Nishigaki K, Thompson D, Hanson C, Yugawa T, Ruscetti S. The envelope glycoprotein of friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase Stk. J Virol, 75: 7893-903, 2001.[Abstract/Free Full Text]
  19. Gaudino G, Avantaggiato V, Follenzi A, et al The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene, 11: 2627-37, 1995.[Medline]
  20. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene, 8: 1195-202, 1993.[Medline]
  21. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, et al Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer, 29: 147-56, 2000.[CrossRef][Medline]
  22. Di Renzo MF, Narsimhan RP, Olivero M, et al Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene, 6: 1997-2003, 1991.[Medline]
  23. Maggiora P, Lorenzato A, Fracchioli S, et al The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res, 288: 382-9, 2003.[CrossRef][Medline]
  24. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet, 25: 217-22, 2000.[CrossRef][Medline]
  25. Waltz SE, Toms CL, McDowell SA, et al Characterization of the mouse Ron/Stk receptor tyrosine kinase gene. Oncogene, 16: 27-42, 1998.[CrossRef][Medline]
  26. Thompson EW, Paik S, Brunner N, et al Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol, 150: 534-44, 1992.[CrossRef][Medline]
  27. Di Renzo MF, Olivero M, Martone T, et al Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19: 1547-55, 2000.[CrossRef][Medline]
  28. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol, 19(Suppl 18): 32S-40S, 2001.
  29. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol, 153: 1049-60, 2001.[Abstract/Free Full Text]
  30. Ji X, Woodard AS, Rimm DL, Fearon ER. Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ, 8: 773-8, 1997.[Abstract]
  31. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res, 62: 1613-8, 2002.[Abstract/Free Full Text]
  32. Batlle E, Sancho E, Franci C, et al The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol, 2: 84-9, 2000.[CrossRef][Medline]
  33. Cano A, Perez-Moreno MA, Rodrigo I, et al The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol, 2: 76-83, 2000.[CrossRef][Medline]
  34. Perez-Moreno MA, Locascio A, Rodrigo I, et al A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem, 276: 27424-31, 2001.[Abstract/Free Full Text]
  35. Comijn J, Berx G, Vermassen P, et al The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell, 7: 1267-78, 2001.[CrossRef][Medline]
  36. Waltz SE, Eaton L, Toney-Earley K, et al Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Investig, 108: 567-76, 2001.[CrossRef][Medline]
  37. Nagane M, Coufal F, Lin H, et al A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res, 56: 5079-86, 1996.[Abstract/Free Full Text]
  38. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat, 12: 226-37, 1998.[CrossRef][Medline]
  39. Graff JR, Herman JG, Lapidus RG, et al E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res, 55: 5195-9, 1995.[Abstract/Free Full Text]
  40. Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene, 18: 7274-9, 1999.[CrossRef][Medline]
  41. Fujita Y, Krause G, Scheffner M, et al Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol, 4: 222-31, 2002.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. D. Cardamone, C. Bardella, A. Gutierrez, L. Di Croce, M. G. Rosenfeld, M. F. Di Renzo, and M. De Bortoli
ER{alpha} as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells
PNAS, May 5, 2009; 106(18): 7420 - 7425.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Zhang, H.-P. Yao, and M.-H. Wang
Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility
Carcinogenesis, March 1, 2008; 29(3): 552 - 559.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Thangasamy, J. Rogge, and S. Ammanamanchi
Regulation of RON Tyrosine Kinase-mediated Invasion of Breast Cancer Cells
J. Biol. Chem., February 29, 2008; 283(9): 5335 - 5343.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. M. Jelacic, D. Thompson, C. Hanson, J. L. Cmarik, K. Nishigaki, and S. Ruscetti
The Tyrosine Kinase sf-Stk and Its Downstream Signals Are Required for Maintenance of Friend Spleen Focus-Forming Virus-Induced Fibroblast Transformation
J. Virol., January 1, 2008; 82(1): 419 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Brief Funct Genomic ProteomicHome page
D. Angeloni
Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease
Brief Funct Genomic Proteomic, May 24, 2007; (2007) elm007v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. C. Wetzel, M. A. Leonis, A. Dent, M. A. Olson, A. M. Longmeier, P. A. Ney, G. P. Boivin, S. A. Kader, C. C. Caldwell, S. J. F. Degen, et al.
Short-form Ron receptor is required for normal IFN-{gamma} production in concanavalin A-induced acute liver injury
Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G253 - G261.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Nishigaki, C. Hanson, T. Jelacic, D. Thompson, and S. Ruscetti
Friend spleen focus-forming virus transforms rodent fibroblasts in cooperation with a short form of the receptor tyrosine kinase Stk
PNAS, October 25, 2005; 102(43): 15488 - 15493.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. R. Camp, W. Liu, F. Fan, A. Yang, R. Somcio, and L. M. Ellis
RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis
Ann. Surg. Oncol., April 1, 2005; 12(4): 273 - 281.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bardella, C.
Right arrow Articles by Di Renzo, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bardella, C.
Right arrow Articles by Di Renzo, M. F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online